
The standard treatment for stage I zzso cell lung cancer zzso is zzso However, a considerable number of patients are not eligible for standard lung surgery due to poor pulmonary function or zzso We evaluated the efficacy and zzso of zzso zzso zzso zzso with moderate zzso for these zzso Twelve patients were selected for zzso zzso planning was performed by gating zzso zzso The applied doses ranged between zzso zzso zzso zzso zzso zzso zzso zzso and zzso zzso zzso zzso zzso follow-up was performed including zzso and CT for evaluation of local, zzso and distant zzso Even in patients with poor pulmonary function zzso was safe and well zzso No severe acute adverse effects were zzso zzso local control at zzso was zzso Moreover, zzso does not induce a significant deterioration of pulmonary zzso zzso is safe and feasible even for patients with very poor pulmonary zzso The applied dose provides a high local control rate, although the biological equivalent dose zzso is lower compared to the average of other zzso zzso zzso zzso may be an efficient alternative for all zzso stage I patients with zzso to standard zzso especially in patients with small tumors in high-risk zzso 

